Chongqing Zhifei Biological Products Co., Ltd. (SHE: 300122)

Chongqing Zhifei Biological Products Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Operating Revenue	36,428	52,914	38,260	30,629	15,156	10,525
Other Revenue	4.08	4.08	3.85	23.46	34.23	61.91
Revenue	36,432	52,918	38,264	30,652	15,190	10,587
Revenue Growth (YoY)	-26.71%	38.30%	24.83%	101.79%	43.48%	102.50%
Cost of Revenue	27,409	38,997	25,518	15,728	9,316	6,154
Gross Profit	9,023	13,921	12,746	14,925	5,875	4,433
Selling, General & Admin	3,280	3,155	2,595	2,121	1,410	1,278
Research & Development	1,015	968.47	854.16	552.63	299.65	169.55
Other Operating Expenses	325.39	238.75	177.02	135.23	70.99	51.41
Operating Expenses	5,011	4,715	4,047	3,000	1,863	1,567
Operating Income	4,013	9,206	8,698	11,924	4,011	2,866
Interest Expense	-107.09	-81	-53.3	-56.14	-127.14	-76.11
Interest & Investment Income	78.6	67.94	46.09	61.47	11.98	10.85
Currency Exchange Gain (Loss)	2.28	2.28	15.4	-10.1	3.84	1.91
Other Non Operating Income (Expenses)	-23.45	-36.56	-22.64	-17.23	-19.61	-11.46
EBT Excluding Unusual Items	3,963	9,159	8,684	11,902	3,880	2,791
Gain (Loss) on Sale of Investments	-	-	-	-5.63	-13.33	-1.07
Gain (Loss) on Sale of Assets	-1.81	41.37	0.01	0.04	-0	0
Asset Writedown	88.61	-0.13	-0.09	-1.68	-0.55	-0.73
Other Unusual Items	151.48	142.34	34.31	35.83	-12.34	-23.93
Pretax Income	4,201	9,342	8,718	11,931	3,854	2,765
Income Tax Expense	511.01	1,272	1,179	1,723	552.75	398.94
Net Income	3,690	8,070	7,539	10,209	3,301	2,366
Net Income to Common	3,690	8,070	7,539	10,209	3,301	2,366
Net Income Growth	-56.39%	7.04%	-26.15%	209.23%	39.51%	63.05%
Shares Outstanding (Basic)	2,397	2,400	2,400	2,400	2,400	2,400
Shares Outstanding (Diluted)	2,397	2,400	2,400	2,400	2,400	2,400
Shares Change (YoY)	-0.12%	-0.00%	0.00%	-0.00%	0.00%	-0.00%
EPS (Basic)	1.54	3.36	3.14	4.25	1.38	0.99
EPS (Diluted)	1.54	3.36	3.14	4.25	1.38	0.99
EPS Growth	-56.34%	7.04%	-26.15%	209.23%	39.50%	63.06%
Free Cash Flow	2,331	7,862	535.93	6,575	2,670	794.06
Free Cash Flow Per Share	0.97	3.28	0.22	2.74	1.11	0.33
Dividend Per Share	0.800	0.800	0.333	0.400	0.333	0.333
Dividend Growth	140.02%	140.02%	-16.68%	20.01%	0%	0%
Gross Margin	24.77%	26.31%	33.31%	48.69%	38.67%	41.87%
Operating Margin	11.01%	17.40%	22.73%	38.90%	26.41%	27.07%
Profit Margin	10.13%	15.25%	19.70%	33.30%	21.73%	22.35%
Free Cash Flow Margin	6.40%	14.86%	1.40%	21.45%	17.57%	7.50%
EBITDA	4,324	9,515	9,003	12,297	4,132	2,954
EBITDA Margin	11.87%	17.98%	23.53%	40.12%	27.20%	27.91%
D&A For EBITDA	311.87	308.87	304.88	372.24	120.93	88.51
EBIT	4,013	9,206	8,698	11,924	4,011	2,866
EBIT Margin	11.01%	17.40%	22.73%	38.90%	26.41%	27.07%
Effective Tax Rate	12.16%	13.62%	13.52%	14.44%	14.34%	14.43%
Revenue as Reported	36,432	52,918	38,264	30,652	15,190	10,587
Advertising Expenses	-	475.81	395.05	-	-	-

Source: S&P Capital IQ. Standard template. Financial Sources.